` IGN (Inno-Gene SA) vs WIG20 Comparison - Alpha Spread

I
IGN
vs
W
WIG20

Over the past 12 months, IGN has underperformed WIG20, delivering a return of 0% compared to the WIG20's +41% growth.

Stocks Performance
IGN vs WIG20

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
IGN vs WIG20

Loading
IGN
WIG20
Difference
www.alphaspread.com

Performance By Year
IGN vs WIG20

Loading
IGN
WIG20
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Inno-Gene SA vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Inno-Gene SA
Glance View

Inno Gene SA engages in the management of startup biotechnology companies. The company is headquartered in Poznan, Woj. Wielkopolskie. The company went IPO on 2011-02-08. Inno-Gene SA’s portfolio comprises of Centrum Badan DNA Sp. z o.o., a company that provides services in the field of genetic medical diagnostics, including microbiological diagnosis of infection and the suitability of human congenital diseases using tests performed on DNA microarray technology. On March 22, 2013, the Company established a new subsidiary, Centrum Edukacji Bio-Medycznej Sp. z o.o. On April 11, 2013, the Company established two new indirect subsidiaries, Genomix Sp. z o.o. and Madgenetix Sp. z o.o. In addition, it operates through VitainSillica Sp z o o.

IGN Intrinsic Value
2.67 PLN
Overvaluation 47%
Intrinsic Value
Price
I
Back to Top